Introduction
Fenclofenac has been investigated in three separate studies. In the first study its efficacy and tolerance was assessed on an open basis in a group of 21 patients suffering from severe active rheumatoid arthritis who were either intolerant or unresponsive to other non-steroidal anti-inflammatory drugs. The alimentary blood loss was measured in 6 patients using the radioactive chromate-tagged red cell technique. As these studies indicated that fenclofenac was a welltolerated and effective anti-inflammatory agent a short-term double-blind cross-over trial was undertaken to compare fenclofenac therapy with phenylbutazone therapy in the treatment of ankylosing spondylitis.
First Study -Open Assessment in Rheumatoid Arthritis Our clinical experience with fenclofenac includes the treatment of 21 patients, all suffering from severe and active rheumatoid arthritis, and intolerant of or refractory to other non-steroidal, analgesic/anti-inflammatory drugs. These patients have been under treatment for periods of 1 to 24 months, the mean duration of therapy being 14 months. In all, 299 months of therapy have been recorded. All other anti-inflammatory drugs were excluded during fenclofenac therapy and any additional analgesics were recorded. Dosage ranged from 600 mg daily to 1200 mg daily, the mean being 900 mg daily. In general the lower doses were given during the earlier stages of the study when caution dictated this policy. The response to fenclofenac was assessed by measurements of grip strength and the duration of morning stiffness, in addition to haematological and biochemical tests. The results are summarized in I Requests for reprints should be addressed to Dr M Thompson has been recorded with one other phenylacetic acid derivative used in the treatment of inflammatory arthritis , while it has been claimed that indomethacin, aspirin, phenylbutazone and ibuprofen do not lower ESR , McConkey et al. 1973 ).
The white cell count fell during treatment in the majority of cases but no leukopenia occurred, nor was there any serious decrease in the platelet counts although the majority of patients did show some reduction. No significant alterations in renal or hepatic function were found in any patient in this series. Seven patients (33 %) were withdrawn for the reasons listed in Table 2 . In 4 cases the reason for withdrawal was drug related (3 rash and 1 dyspepsia); in one case it was not drug related and in 2 cases doubtfully related (one ineffective in lower dosage and one anxiety with dyspepsia).
Allowing that the 21 patients in this series had all failed to respond to, or been intolerant of, other non-steroidal anti-inflammatory drugs, the withdrawal rate is not unduly high. The principal reason for withdrawal has been the occurrence of Mean daily 1.0 1.9 blood loss an acute, diffuse maculopapular rash. In all cases the rash subsided rapidly on withdrawal of the drug and no signs of vasculitis or of visceral involvement were found.
Second Study -Measurement ofAlimentary Blood Loss Studies of gastrointestinal blood loss using the radioactive chromate-tagged red cell technique were undertaken on 6 patients and the blood loss in ml per day was compared with alimentary blood loss measured when the same patients were receiving paracetamol (Table 3 ). The mean blood loss from 41 days of frcal collections during fenclofenac therapy was 1.9 ml per day which is within the accepted normal limit of daily blood loss as estimated by this method, although higher than the control specimens when the patients were receiving paracetamol amounting to 33 days' collections with a mean loss of 1.0 ml per day.
Third Study -Double-blind Comparison ofFenclofenac versus Phenylbutazone in Ankylosing Spondylitis Twenty-three patients were admitted to the third trial, which has been reported previously (Thompson & Akyol 1977). All patients had raised ESR, pain, morning stiffness in excess of 20 minutes' duration and radiographic evidence of sacroiliitis. In 22 of the patients the HLA test for B.27 was positive. On admission to the trial the patients were transferred from their existing therapy to paracetamol for a four-day wash-out period, and then were given either phenylbutazone, in the form of Butacote 300 mg daily, or fenclofenac 1200 mg daily, according to a predetermined randomized series. After 14 days a further wash-out period of paracetamol was given for fout days, and then the patient received the alternative drug therapy for a further 14 days. Fenclofenac was given in the form of white tablets containing 300 mg of the active drug and was administered on a thrice daily basis with one tablet at breakfast time, one tablet at lunch time and two tablets at supper time. Butacote was supplied as pale violet tablets each containing 100 mg of active drug and administered on a thrice daily basis, one tablet at breakfast time, one tablet at lunch time and one tablet at supper time. In view of the differences in appearance of the tablets, matching dummy tablets to both the drugs were employed in the usual manner of clinical trials when dissimilar formulations have to be employed.
The results (Table 4) show that there was no significant difference between the two drugs in terms of the clinical measurements of pain (visual analogue scale) morning stiffness, spinal mobility, chest expansion and abduction of the hips. The results favoured Butacote in the expressed preferences of both the patients and physicians conducting the trial (Table 5 ). The side-effects are shown in Table 6 . Six patients reported a mild maculopapular rash while receiving fenclofenac therapy. In 5 of the 6 cases the rash was probably drug related and this was the outstanding factor which determined the patients' and doctors' preferences. Summary Fenclofenac has been assessed in three separate studies. It was used in the treatment of 21 patients suffering from rheumatoid arthritis, the mean duration of therapy being 14 months. All the patients had failed to respond to, or been intolerant of, previously administered anti-inflammatory drugs. The response to fenclofenac was good in terms of symptomatic relief and the ESR was reduced in 18 of the 21 patients. No serious adverse side-effects were encountered but the drug was withdrawn in 3 patients because of the abrupt development of a maculopapular rash and in 2 patients who complained of dyspepsia. Studies of alimentary blood loss using the 5'Cr-tagged red cell technique indicated that fenclofenac did not cause any significant alimentary bleeding. Ih a two-week cross-over study comparing fenclofenac therapy (1200 mg daily) with phenylbutazone therapy (Butacote 300 mg daily) in 23 patients suffering from ankylosing spondylitis there were no significant differences seen between the two drugs in terms of the clinical measurements of pain, morning stiffness, spinal mobility, chest expansion and abduction of the hips. Both drugs were effective in controlling the symptoms of the disease but the results favoured Butacote in the expressed preferences of the patients and physicians conducting the trial. No severe side-effects occurred during the trial but 5 patients developed a maculopapular rash during the fenclofenac treatment period.
